Market Overview

Maxim Raises Price Target On Viking Therapeutics From $8 To $14 As Stock Sees Strength In Sympathy With MDGL, Says 'Success for Madrigal is a Positive For Viking and VK2809'

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for VKTX

DateFirmActionFromTo
Jul 2019Initiates Coverage OnOutperform
Jun 2019Initiates Coverage OnBuy
Mar 2019UpgradesMarket PerformOutperform

View More Analyst Ratings for VKTX
View the Latest Analyst Ratings

Posted-In: Biotech News Price Target FDA Analyst Ratings General

 

Related Articles (VKTX + MDGL)

Latest Ratings

StockFirmActionPT
FTVMorgan StanleyMaintains70.0
ROKMorgan StanleyMaintains142.0
WWEFBN SecuritiesUpgrades100.0
SWNCapital One FinancialUpgrades
AEISCowen & Co.Downgrades57.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Mid-Day Market Update: Dow Down Over 250 Points; Madrigal Pharmaceuticals Shares Spike Higher

Loxo Oncology's Candidates Are 'Impressive,' Piper Jaffray Says In Bullish Initiation